The company said revenue for the second quarter was $115.8 million (end-June 30, 2021), up from $42.9 million in the second quarter of 2020. The increase can be attributed to greater consumables revenue driven by growth in the instrument-installed base, along with the decreased impact of the pandemic on customer operations, 10x Genomics added.

Among the highlights for the quarter, the company launched its single cell analysis platform Chromium X; began shipping Visium Spatial Gene Expression for formalin-fixed, paraffin-embedded (FFPE) samples; and entered into a global settlement and cross-license agreement with Bio-Rad Laboratories.

10x Genomics inks license deal with Bio-Rad
10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.

10x Genomics launches FFPE Visium assay for research use
10x Genomics has launched its new Visium Spatial Gene Expression assay for formalin-fixed, paraffin-embedded (FFPE) samples, which gives researchers the...

10x Genomics launches low-throughput gene expression kit
10x Genomics has launched its chromium single-cell gene expression low-throughput kit, a new offering designed to enable single cell analysis.

Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...